 associated with a 28%
mortality rate5 and a 16% paraplegia rate.6 There has been
a risk of delayed rupture in the unrepaired thoracic transection that has been estimated to be 2% to 5%.7
Thoracic endovascular aortic repair (TEVAR) is a rapidly evolving therapy in the treatment of a variety of thoracic aortic pathologies. TEVAR involves placing an endovascular stent graft into the